[PDF][PDF] SARS-CoV-2 reverse genetics reveals a variable infection gradient in the respiratory tract

YJ Hou, K Okuda, CE Edwards, DR Martinez… - Cell, 2020 - cell.com
YJ Hou, K Okuda, CE Edwards, DR Martinez, T Asakura, KH Dinnon, T Kato, RE Lee…
Cell, 2020cell.com
The mode of acquisition and causes for the variable clinical spectrum of coronavirus disease
2019 (COVID-19) remain unknown. We utilized a reverse genetics system to generate a
GFP reporter virus to explore severe acute respiratory syndrome coronavirus 2 (SARS-CoV-
2) pathogenesis and a luciferase reporter virus to demonstrate sera collected from SARS
and COVID-19 patients exhibited limited cross-CoV neutralization. High-sensitivity RNA in
situ mapping revealed the highest angiotensin-converting enzyme 2 (ACE2) expression in …
Summary
The mode of acquisition and causes for the variable clinical spectrum of coronavirus disease 2019 (COVID-19) remain unknown. We utilized a reverse genetics system to generate a GFP reporter virus to explore severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pathogenesis and a luciferase reporter virus to demonstrate sera collected from SARS and COVID-19 patients exhibited limited cross-CoV neutralization. High-sensitivity RNA in situ mapping revealed the highest angiotensin-converting enzyme 2 (ACE2) expression in the nose with decreasing expression throughout the lower respiratory tract, paralleled by a striking gradient of SARS-CoV-2 infection in proximal (high) versus distal (low) pulmonary epithelial cultures. COVID-19 autopsied lung studies identified focal disease and, congruent with culture data, SARS-CoV-2-infected ciliated and type 2 pneumocyte cells in airway and alveolar regions, respectively. These findings highlight the nasal susceptibility to SARS-CoV-2 with likely subsequent aspiration-mediated virus seeding to the lung in SARS-CoV-2 pathogenesis. These reagents provide a foundation for investigations into virus-host interactions in protective immunity, host susceptibility, and virus pathogenesis.
cell.com